Spondyloarthritis & psoriatic arthritis
Bimekizumab-Treated Patients with Axial Spondyloarthritis Maintained Stringent Clinical Responses Over 3 Years: Phase 3 and Open-Label Extension Results
Authors' conclusion
In this exploratory analysis, across the full axSpA disease spectrum, the majority of patients who achieved stringent clinical outcomes with bimekizumab treatment at Week 16 maintained their response over three years, supporting deep and sustained efficacy with long-term bimekizumab treatment.
Study context
- Population
- Bimekizumab-randomised patients with axial spondyloarthritis (non-radiographic and radiographic axial spondyloarthritis (axSpA)) from BE MOBILE 1 and 2 and their open-label extension
- Participants
- 349 bimekizumab-randomised patients
Methodological detailspooled across BE MOBILE 1 and 2, descriptive, non-responder imputation (NRI), modified NRI (mNRI), multiple imputation (MI) or observed case (OC)
- Pooled across BE MOBILE 1 and 2
- Descriptive
- Non-responder imputation (NRI), modified NRI (mNRI), multiple imputation (MI) or observed case (OC)
Primary result
As reported in the abstract
ASAS40
45.8%
ASAS PR
24.6%
ASDAS LDA
43.6%
ASDAS ID
16.6%
Further findings
Sustained achievement at Week 164 among Week 16 achievers (ASAS40/ASAS PR/ASDAS LDA/ASDAS ID)
- ASAS40, of Week 16 achievers
- 80.4%
- ASAS PR, of Week 16 achievers
- 66.3%
- ASDAS LDA, of Week 16 achievers
- 78.8%
- ASDAS ID, of Week 16 achievers
- 61.0%
- mNRI/MI
Pain/fatigue reduction and resolution of enthesitis
- Similar trends were observed
Response maintained at every visit to Week 164 among Week 16 achievers of ASDAS LDA and BASDAI <2
- ASDAS LDA, of Week 16 achievers
- 36.2%
- BASDAI <2, of Week 16 achievers
- 38.0%
- As observed
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →